Amendments to the Claims:

Claim 1. (Currently amended): ~~Use~~ A method for the treatment of myocardial infarction, myocardial ischaemia, coronary vasospasm, angina and cardiac failure which comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I):



(I)

in which:

- R_1 represents a halogen or a CF_3, $(C_1$-$C_4)$alkyl or $(C_1$-$C_4)$alkoxy group;
- Y represents a nitrogen atom ~~or a CH group~~;
- Z' and Z" each represent hydrogen or a $(C_1$-$C_3)$ alkyl group, or one represents hydrogen and the other a hydroxy group, or both, together, represent an oxo group;
- Z represents
  - a phenyl radical;
  - a phenyl radical monosubstituted with a substituent X, X being
    a) a $(C_1$-$C_6)$alkyl; $(C_1$-$C_6)$alkoxy; $(C_3$-$C_7)$carboxyalkyl; $(C_1$-$C_4)$alkoxycarbonyl$(C_1$-$C_6)$alkyl; $(C_3$-$C_7)$carboxyalkoxy or $(C_1$-$C_4)$-alkoxycarbonyl$(C_1$-$C_6)$alkoxy group;
    b) a group selected from a $(C_3$-$C_7)$cycloalkyl, $(C_3$-$C_7)$cycloalkyloxy, $(C_3$-$C_7)$cycloalkylmethyl, $(C_3$-$C_7)$cycloalkylamino and cyclohexenyl group, it being possible for said group to be substituted with a halogen, hydroxy, $(C_1$-$C_4)$alkoxy, carboxy, $(C_1$-$C_4)$alkoxycarbonyl, amino, mono- or di-$(C_1$-$C_4)$alkylamino;
    c) a group selected from a phenyl, phenoxy, phenylamino, N-$(C_1$-$C_3)$alkylphenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulphonyl, phenylsulphinyl or styryl, it being possible for said group to be mono- or poly-substituted on the phenyl group with a halogen, CF_3, $(C_1$-$C_4)$alkyl, $(C_1$-$C_4)$alkoxy, cyano, amino, mono- or di-$(C_1$-$C_4)$alkylamino, $(C_1$-$C_4)$acylamino, carboxy, $(C_1$-$C_4)$alkoxycarbonyl, aminocarbonyl, mono- or di-$(C_1$-$C_4)$alkylaminocarbonyl, amino$(C_1$-$C_4)$alkyl, hydroxy$(C_1$-$C_4)$alkyl or halo$(C_1$-$C_4)$alkyl;
  - a phenyl radical disubstituted with a substituent R_2, R_2 being a halogen or a hydroxy, methyl, ethyl, $(C_3$-$C_6)$alkyl, $(C_1$-$C_4)$alkoxy or trifluoromethyl group and with a substituent X, X being as defined above;
  - a 1-naphthyl or 2-naphthyl radical;

- a 1-naphthyl or 2-naphthyl radical substituted in positions 5, 6, 7 and/or 8 with one or two hydroxyl groups, one or two (C_1-C_4)alkoxy groups or a 6,7-methylenedioxy group;

- or Z" is hydrogen and Z and Z' represent, each independently, a non-substituted or mono-, di- or tri-substituted phenyl group;

or ~~of one of its~~ a pharmaceutically acceptable ~~salts and solvates, for the preparation of pharmaceutical compositions capable of increasing circulating and cellular and extracellular levels of TGF-β_1~~ salt or solvate thereof other than a compound in which each of Z' and Z" is hydrogen and Z is 1-naphthyl or 2-naphthyl.

Claims 2-18: Cancelled

Claim 19. (Currently amended): A compound selected from 1-[2-(6,7-methylenedioxynaphth-2-yl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine, 1-[2-(4-cyclohexenylphenyl)-ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetra-hydropyridine and 1-[2-(biphenyl-4-yl)ethyl]-4-(2-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine ~~and their~~ or a pharmaceutically acceptable ~~salts and solvates~~ salt or solvate thereof.

Claim 20. (New) A pharmaceutical composition comprising a compound according to Claim 19 and a pharmaceutically acceptable carrier.

Claim 21. (New) A method for the treatment of pathologies linked to an abnormal apoptotic activity which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 19.